Aliases & Classifications for Ureter, Cancer of

MalaCards integrated aliases for Ureter, Cancer of:

Name: Ureter, Cancer of 57
Ureter Carcinoma 12 55 15 73
Ureteral Benign Neoplasm 12 15
Ureteral Neoplasms 44 73
Ureter Cancer 12 15
Malignant Neoplasm of Ureter 73
Malignant Tumour of Ureter 12
Malignant Ureteral Tumor 12
Neoplasm of Ureter 12
Ureteral Carcinoma 12
Ureteral Tumor 12



autosomal dominant


ureter, cancer of:
Inheritance autosomal dominant inheritance


External Ids:

OMIM 57 191600
Disease Ontology 12 DOID:11819 DOID:11885 DOID:4939
ICD10 33 C66
ICD9CM 35 189.2
MeSH 44 D014516
MedGen 42 C0153619
SNOMED-CT via HPO 69 263681008

Summaries for Ureter, Cancer of

Disease Ontology : 12 An ureter cancer that is located in the ureter.

MalaCards based summary : Ureter, Cancer of, also known as ureter carcinoma, is related to regional ureteric cancer and ureter adenocarcinoma. An important gene associated with Ureter, Cancer of is PLAUR (Plasminogen Activator, Urokinase Receptor), and among its related pathways/superpathways are Lung fibrosis and Cell adhesion_ECM remodeling. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include the ureter, kidney and endothelial, and related phenotype is neoplasm of the ureter.

Wikipedia : 76 Ureteral cancer is cancer of the ureters, muscular tubes that propel urine from the kidneys to the... more...

Description from OMIM: 191600

Related Diseases for Ureter, Cancer of

Diseases related to Ureter, Cancer of via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 regional ureteric cancer 11.1
2 ureter adenocarcinoma 11.0
3 kidney benign neoplasm 10.9
4 perforated corneal ulcer 10.6 PLAU PLAUR
5 paranasal sinus disease 10.4 PLAU PLAUR
6 hemoglobinuria 10.2 PLAU PLAUR
7 paroxysmal nocturnal hemoglobinuria 10.2 PLAU PLAUR
8 spermatocele 10.2 SYP TERT
9 esophageal neuroendocrine tumor 10.2 CHGA SYP
10 ureter small cell carcinoma 10.2 CHGA SYP
11 urinary bladder small cell neuroendocrine carcinoma 10.2 CHGA SYP
12 ovarian large-cell neuroendocrine carcinoma 10.2 CHGA SYP
13 auditory system cancer 10.2 CHGA SYP
14 adenoma of the pancreas 10.2 CHGA SYP
15 acinar cell cystadenocarcinoma 10.2 CHGA SYP
16 peritoneal serous adenocarcinoma 10.2 CHGA SYP
17 cellular ependymoma 10.2 CHGA SYP
18 gallbladder small cell carcinoma 10.2 CHGA SYP
19 primary hepatic neuroendocrine carcinoma 10.1 CHGA SYP
20 small cell carcinoma of the bladder 10.1 CHGA SYP
21 gastrointestinal neuroendocrine tumor 10.1 CHGA SYP
22 pulmonary large cell neuroendocrine carcinoma 10.1 CHGA SYP
23 atypical follicular adenoma 10.1 CHGA SYP
24 chordoid meningioma 10.1 CHGA SYP
25 olfactory nerve neoplasm 10.1 CHGA SYP
26 cauda equina neoplasm 10.1 CHGA SYP
27 conventional angiosarcoma 10.1 CHGA SYP
28 nodular ganglioneuroblastoma 10.1 CHGA SYP
29 pulmonary sclerosing hemangioma 10.1 CHGA SYP
30 pineocytoma 10.1 CHGA SYP
31 respiratory system benign neoplasm 10.1 CHGA SYP
32 gastric squamous cell carcinoma 10.1 CHGA SYP
33 gastric small cell carcinoma 10.1 CHGA SYP
34 pancreatoblastoma 10.1 CHGA SYP
35 cystitis cystica 10.1 SYP TERT
36 subependymoma 10.1 CHGA SYP
37 carcinoid tumors, intestinal 10.1 CHGA SYP
38 pulmonary blastoma 10.1 CHGA SYP
39 tanycytic ependymoma 10.1 CHGA SYP
40 papillary ependymoma 10.1 CHGA SYP
41 non-functioning pancreatic endocrine tumor 10.1 CHGA SYP
42 pleomorphic xanthoastrocytoma 10.1 CHGA SYP
43 sclerosing hemangioma 10.1 CHGA SYP
44 central neurocytoma 10.1 CHGA SYP
45 pancreatic cystadenocarcinoma 10.1 CHGA SYP
46 binswanger's disease 10.1 CHGA SYP
47 carcinoid syndrome 10.1 CHGA SYP
48 cranial nerve malignant neoplasm 10.1 CHGA SYP
49 cervix small cell carcinoma 10.0 CHGA SYP
50 olfactory neuroblastoma 10.0 CHGA SYP

Comorbidity relations with Ureter, Cancer of via Phenotypic Disease Network (PDN):

Acute Cystitis Bladder Cancer
Deficiency Anemia Hydronephrosis
Prostatic Hypertrophy Renal Pelvis Carcinoma

Graphical network of the top 20 diseases related to Ureter, Cancer of:

Diseases related to Ureter, Cancer of

Symptoms & Phenotypes for Ureter, Cancer of

Symptoms via clinical synopsis from OMIM:

cancer of ureter

Clinical features from OMIM:


Human phenotypes related to Ureter, Cancer of:

# Description HPO Frequency HPO Source Accession
1 neoplasm of the ureter 32 HP:0100516

Drugs & Therapeutics for Ureter, Cancer of

Drugs for Ureter, Cancer of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 84093 441203 2767
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 11953898 44475014
Pemetrexed Approved, Investigational Phase 3,Phase 2 150399-23-8, 137281-23-3 446556 60843
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
Bevacizumab Approved, Investigational Phase 3 216974-75-3
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 3,Phase 2 13422-55-4
Doxil Approved June 1999 Phase 3,Phase 1,Phase 2 31703
16 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
17 Anti-Infective Agents Phase 3,Phase 1,Phase 2
18 Antimetabolites Phase 3,Phase 1,Phase 2
19 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
20 Antiviral Agents Phase 3,Phase 1,Phase 2
21 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
22 Antibodies Phase 3,Phase 2,Phase 1
23 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
24 Immunoglobulins Phase 3,Phase 2,Phase 1
25 Antiemetics Phase 3,Phase 2
26 Anti-Inflammatory Agents Phase 3,Phase 2
27 Antineoplastic Agents, Hormonal Phase 3,Phase 2
28 Autonomic Agents Phase 3,Phase 2
29 BB 1101 Phase 3,Phase 2
30 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
31 Folic Acid Antagonists Phase 3,Phase 2
32 Gastrointestinal Agents Phase 3,Phase 2
33 glucocorticoids Phase 3,Phase 2
34 Hematinics Phase 3,Phase 2
35 HIV Protease Inhibitors Phase 3,Phase 2
36 Hormone Antagonists Phase 3,Phase 2,Phase 1
37 Hormones Phase 3,Phase 2,Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
39 Micronutrients Phase 3,Phase 2,Phase 1
40 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
protease inhibitors Phase 3,Phase 2
42 Trace Elements Phase 3,Phase 2,Phase 1
43 Vitamin B 12 Phase 3,Phase 2
44 Vitamin B Complex Phase 3,Phase 2,Phase 1
45 Vitamins Phase 3,Phase 2,Phase 1
46 Angiogenesis Inhibitors Phase 3,Phase 1
47 Angiogenesis Modulating Agents Phase 3,Phase 1
48 Endothelial Growth Factors Phase 3,Phase 1
49 Immunoglobulin G Phase 3
50 Mitogens Phase 3,Phase 1

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
2 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
3 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
4 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Active, not recruiting NCT01993979 Phase 3 Chemotherapy
5 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
6 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
7 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
8 Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2 Genexol PM
9 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
10 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
11 Arsenic Trioxide in Treating Patients With Urothelial Cancer Completed NCT00009867 Phase 2 arsenic trioxide
12 Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
13 Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Completed NCT01282463 Phase 2 Docetaxel
14 Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma Recruiting NCT03179943 Phase 2 Atezolizumab;Guadecitabine
15 Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
16 Afatinib in Advanced Refractory Urothelial Cancer Recruiting NCT02122172 Phase 2 afatinib dimaleate
17 A Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma Recruiting NCT02693717 Phase 2 Pemetrexed;Dexamethasone
18 Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT03397394 Phase 2 Rucaparib
19 A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Active, not recruiting NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
20 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Active, not recruiting NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
21 Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Not yet recruiting NCT03520231 Phase 2 Denosumab;Gemcitabine;Carboplatin;Cisplatin
22 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Not yet recruiting NCT03513952 Phase 2 Atezolizumab
23 A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy Terminated NCT01234519 Phase 1, Phase 2 AEZS-108;AEZS-108 at MTD
24 DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Terminated NCT01353222 Phase 2
25 Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer Withdrawn NCT01639521 Phase 2 cisplatin;gemcitabine hydrochloride;methotrexate;vinblastine;doxorubicin hydrochloride
26 Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Completed NCT01182168 Phase 1 gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
27 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
28 Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors Active, not recruiting NCT01352962 Phase 1 Gemcitabine;Carboplatin;Lenalidomide
29 Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Active, not recruiting NCT02300610 Phase 1 Enzalutamide;Cisplatin;Gemcitabine
30 Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Active, not recruiting NCT01844947 Phase 1 Vinflunine;Sorafenib
31 Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Active, not recruiting NCT00479128 Phase 1 Bortezomib;Gemcitabine;Doxorubicin
32 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Active, not recruiting NCT02443324 Phase 1 Ramucirumab;Pembrolizumab
33 CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma Completed NCT03013920
34 Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction. Completed NCT00263107
35 Familial and Atypical Urothelial Cancer Registry Recruiting NCT00902590
36 UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch Recruiting NCT02643043
37 Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma Recruiting NCT03291028
38 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
39 Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers Recruiting NCT01846520 Not Applicable

Search NIH Clinical Center for Ureter, Cancer of

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: ureteral neoplasms

Genetic Tests for Ureter, Cancer of

Anatomical Context for Ureter, Cancer of

The Foundational Model of Anatomy Ontology organs/tissues related to Ureter, Cancer of:

The Ureter

MalaCards organs/tissues related to Ureter, Cancer of:

Kidney, Endothelial, Lung, Bone

Publications for Ureter, Cancer of

Articles related to Ureter, Cancer of:

# Title Authors Year
Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer. ( 24202956 )
Papillary urothelial carcinoma in sigmoid neobladder suggesting 'intraluminal seeding' from ureter cancer. ( 19138291 )
Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer. ( 17725112 )
The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. ( 2606581 )
The Copenhagen case-control study of renal pelvis and ureter cancer: role of smoking and occupational exposures. ( 3356489 )

Variations for Ureter, Cancer of

Expression for Ureter, Cancer of

Search GEO for disease gene expression data for Ureter, Cancer of.

Pathways for Ureter, Cancer of

Pathways related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.17 PLAU TERT
2 11.11 PLAU PLAUR
3 10.94 PLAU PLAUR
4 10.83 PLAU PLAUR
5 10.49 PLAU PLAUR

GO Terms for Ureter, Cancer of

Cellular components related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 specific granule membrane GO:0035579 8.62 PLAU PLAUR

Biological processes related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 8.96 PLAU PLAUR
2 positive regulation of cardiac muscle contraction GO:0060452 8.62 ADRA1A CHGA

Sources for Ureter, Cancer of

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....